Successes and failures of chemokine-pathway targeting in rheumatoid arthritis

doi:10.1038/nrrheum.2015.157

Review

. 2016 Jan;12(1):5-13.

doi: 10.1038/nrrheum.2015.157. Epub 2015 Nov 26.

Successes and failures of chemokine-pathway targeting in rheumatoid arthritis

Zoltán Szekanecz¹, Alisa E Koch²

Affiliations

¹ Department of Rheumatology, Institute of Medicine, University of Debrecen Faculty of Medicine, Nagyerdei Str 98, Debrecen, H-4004, Hungary.
² University of Michigan Health System, Department of Internal Medicine, Division of Rheumatology, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, USA.

PMID: 26607389
DOI: 10.1038/nrrheum.2015.157

Review

Successes and failures of chemokine-pathway targeting in rheumatoid arthritis

Zoltán Szekanecz et al. Nat Rev Rheumatol. 2016 Jan.

. 2016 Jan;12(1):5-13.

doi: 10.1038/nrrheum.2015.157. Epub 2015 Nov 26.

Authors

Zoltán Szekanecz¹, Alisa E Koch²

Affiliations

¹ Department of Rheumatology, Institute of Medicine, University of Debrecen Faculty of Medicine, Nagyerdei Str 98, Debrecen, H-4004, Hungary.
² University of Michigan Health System, Department of Internal Medicine, Division of Rheumatology, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, USA.

PMID: 26607389
DOI: 10.1038/nrrheum.2015.157

Abstract

Chemokines and chemokine receptors are involved in leukocyte recruitment and angiogenesis underlying the pathogenesis of rheumatoid arthritis (RA) and other inflammatory rheumatic diseases. Numerous chemokines, along with both conventional and atypical cell-surface chemokine receptors, are found in inflamed synovia. Preclinical studies carried out in animal models of arthritis involving agents targeting chemokines and chemokine receptors have yielded promising results. However, most human trials of treatment of RA with antibodies and synthetic compounds targeting chemokine signalling have failed to show clinical improvements. Chemokines can have overlapping actions, and their activities can be altered by chemical modification or proteolytic degradation. Effective targeting of chemokine pathways must take acount of these properties, and can also require high levels of receptor occupancy by therapeutic agents to prevent signalling. CCR1 is a promising target for chemokine-receptor blockade.

PubMed Disclaimer

Cited by

Astilbin-induced inhibition of the PI3K/AKT signaling pathway decelerates the progression of osteoarthritis.
Chen C, Yang M, Chen Y, Wang Y, Wang K, Li T, Hu Q, Zhang W, Xia J. Chen C, et al. Exp Ther Med. 2020 Oct;20(4):3078-3083. doi: 10.3892/etm.2020.9048. Epub 2020 Jul 27. Exp Ther Med. 2020. PMID: 32855675 Free PMC article.
Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2.
Ortiz Zacarías NV, van Veldhoven JPD, Portner L, van Spronsen E, Ullo S, Veenhuizen M, van der Velden WJC, Zweemer AJM, Kreekel RM, Oenema K, Lenselink EB, Heitman LH, IJzerman AP. Ortiz Zacarías NV, et al. J Med Chem. 2018 Oct 25;61(20):9146-9161. doi: 10.1021/acs.jmedchem.8b00605. Epub 2018 Oct 11. J Med Chem. 2018. PMID: 30256641 Free PMC article.
Gpr174 Knockout Alleviates DSS-Induced Colitis via Regulating the Immune Function of Dendritic Cells.
Wei W, Mu S, Han Y, Chen Y, Kuang Z, Wu X, Luo Y, Tong C, Zhang Y, Yang Y, Song Z. Wei W, et al. Front Immunol. 2022 May 20;13:841254. doi: 10.3389/fimmu.2022.841254. eCollection 2022. Front Immunol. 2022. PMID: 35669778 Free PMC article.
NR1D1 modulates synovial inflammation and bone destruction in rheumatoid arthritis.
Liu H, Zhu Y, Gao Y, Qi D, Zhao L, Zhao L, Liu C, Tao T, Zhou C, Sun X, Guo F, Xiao J. Liu H, et al. Cell Death Dis. 2020 Feb 18;11(2):129. doi: 10.1038/s41419-020-2314-6. Cell Death Dis. 2020. PMID: 32071294 Free PMC article.
Platelet-derived extracellular vesicles promote the migration and invasion of rheumatoid arthritis fibroblast-like synoviocytes via CXCR2 signaling.
Wang W, Deng Z, Liu G, Yang J, Zhou W, Zhang C, Shen W, Zhang Y. Wang W, et al. Exp Ther Med. 2021 Oct;22(4):1120. doi: 10.3892/etm.2021.10554. Epub 2021 Aug 4. Exp Ther Med. 2021. PMID: 34504574 Free PMC article.

See all "Cited by" articles

References

1. Arthritis Rheum. 2010 Nov;62(11):3154-60 - PubMed
1. Arthritis Res Ther. 2007;9(5):R94 - PubMed
1. Ann Rheum Dis. 2010 Nov;69(11):2013-6 - PubMed
1. Rheumatology (Oxford). 2006 Apr;45(4):421-4 - PubMed
1. Science. 1992 Dec 11;258(5089):1798-801 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information

[1] Arthritis Rheum. 2010 Nov;62(11):3154-60 - PubMed

[2] Arthritis Rheum. 2010 Nov;62(11):3154-60 - PubMed

[3] Arthritis Res Ther. 2007;9(5):R94 - PubMed

[4] Arthritis Res Ther. 2007;9(5):R94 - PubMed

[5] Ann Rheum Dis. 2010 Nov;69(11):2013-6 - PubMed

[6] Ann Rheum Dis. 2010 Nov;69(11):2013-6 - PubMed

[7] Rheumatology (Oxford). 2006 Apr;45(4):421-4 - PubMed

[8] Rheumatology (Oxford). 2006 Apr;45(4):421-4 - PubMed

[9] Science. 1992 Dec 11;258(5089):1798-801 - PubMed

[10] Science. 1992 Dec 11;258(5089):1798-801 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Successes and failures of chemokine-pathway targeting in rheumatoid arthritis

Affiliations

Successes and failures of chemokine-pathway targeting in rheumatoid arthritis

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical